Rates of Breast, Ovarian Cancer High Among Jewish Women without Family History

Share this content:

the Cancer Therapy Advisor take:

According to new research published in the Proceedings of the National Academy of Sciences, women of Ashkenazi Jewish descent who tested positive for breast cancer 1 and 2, early onset (BRCA1 and BRCA2), have high rates of breast and ovarian cancer despite no family history of the disease.

 

In the study, researchers first tested more than 8,000 Ashkenazi men 30 years and older without cancer and identified 175 men that carried a BRCA 1 or BRCA2 mutation. Then, researchers tested female relatives of the male carriers and identified 211 with the BRCA1 or BRCA2 mutation. Of those, approximately 50% had little to no family history of cancer.

 

Despite having no family history, those women had high rates of cancer. Of the women aged 60 and older, about 60% of BRCA1 carriers and 33% of BRCA2 carriers had developed breast or ovarian cancer. Of those aged 80 and older, 83% of BRCA1 carriers and 76% of BRCA2 carriers had breast or ovarian cancer.

 

The study suggests that despite little to no family history of breast or ovarian cancer, Ashkenazi Jewish women should be tested for a genetic mutation predisposing them to cancer. Early detection can help patients and clinicians to determine whether risk-reducing options are appropriate.

Rates of Breast and Ovarian Cancer High Among Jewish Women without Family History
Ashkenazi Jewish women have high rates despite no family history.

Women of Ashkenazi Jewish descent who tested positive for cancer-causing genetic mutations during random screenings have high rates of breast and ovarian cancer even when they have no family history of the disease, researchers reported Thursday.

The finding calls into question the practice of screening women — particularly women of Ashkenazi descent, as are most Jews in the United States — for these mutations only if they report that many women in their family have had cancer. Some women are tested for mutations only after they develop cancer themselves.

READ FULL ARTICLE From The New York Times

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs